Asset Details
Do you wish to reserve the book?
Disproportionality analysis of infection associated with antidiabetic drug use patterns
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Disproportionality analysis of infection associated with antidiabetic drug use patterns
Do you wish to request the book?
Disproportionality analysis of infection associated with antidiabetic drug use patterns
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Disproportionality analysis of infection associated with antidiabetic drug use patterns
2025
Overview
While various antidiabetic drug classes are associated with differing infection risks, comprehensive evidence on infection risk across multidrug regimens remains limited. Therefore, this study aims to investigate the pharmacovigilance signal between antidiabetic drug use and infection risk, considering the number and patterns of drug use. This study evaluated the pharmacovigilance signal between antidiabetic drug use and infection utilizing the global pharmacovigilance database. To account for adverse events from multiple drug use, we restructured the database at the individual level using a unique demographic identifier, allowing assessment of infection risk by drug combination and count. Antidiabetic drugs include metformin, sulfonylureas, dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 receptor agonists (GLP-1 RAs), sodium-glucose cotransporter-2 (SGLT2) inhibitors, thiazolidinediones, alpha-glucosidase inhibitors, and insulin, with infections categorized by the system. The pharmacovigilance signal of adverse drug reactions was estimated using adjusted reporting odds ratios (aRORs) with 95% confidence intervals (CIs) through multivariable logistic regression. SGLT2 inhibitor users reported the highest frequency of infections (
n
= 13,570), followed by insulin (
n
= 11,322) and GLP-1 RAs (
n
= 5966). When analyzing only monotherapy, excluding combination use, urinary tract infections were significantly linked solely to SGLT2 inhibitors (aROR, 10.41 [95% CI, 9.76–11.09]), while hepatobiliary and pancreatic infections were associated with DPP-4 inhibitors (aROR, 1.72 [95% CI, 1.28–2.31]), with no significant pharmacovigilance signal observed for other drug classes. Compared to monotherapy, combination therapy with two drugs (aROR, 1.24 [95% CI, 1.20–1.29]) or three or more drugs (aROR, 1.42 [95% CI, 1.13–1.79]) was associated with infection. Although the results from disproportionality analysis did not indicate causal relationship, our findings indicate that infection types vary between monotherapy and combination therapy, highlighting the need for further investigation into these pharmacovigilance signal due to the increased susceptibility of individuals with diabetes.
Publisher
Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
Subject
/ 692/163
/ 692/308
/ 692/699
/ Adult
/ Aged
/ Diabetes
/ Dipeptidyl-Peptidase IV Inhibitors - adverse effects
/ Drug use
/ Female
/ Glucagon
/ Humanities and Social Sciences
/ Humans
/ Hypoglycemic Agents - adverse effects
/ Hypoglycemic Agents - therapeutic use
/ Insulin
/ Male
/ Science
/ Sodium-glucose cotransporter
